Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats.
Antimicrobial agents and chemotherapy • Vol. 61, Issue 11 • 2017
Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy • Vol. 59, Issue 8 • 2015
Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.
Antimicrobial agents and chemotherapy • Vol. 57, Issue 5 • 2013
